New heart failure implant ends “clash of technologies”

MUHC cardiac patient first in Canada to receive a cardiac resynchronization therapy defibrillator with full-body MRI compatibility.

Montreal, July 17, 2017 – A patient from the McGill University Health Centre (MUHC) with heart failure has successfully received a Cardiac Resynchronization Therapy Defibrillator (CRT-D) that will allow him to safely undergo full-body magnetic resonance imaging (MRI) scans. Although "traditional" CRT-Ds are frequently used, this is the first time the device called Amplia MRI™ Quad CRT-D SureScan has been implanted in Canada. 

Montreal, July 17, 2017 – A patient from the McGill University Health Centre (MUHC) with heart failure has successfully received a Cardiac Resynchronization Therapy Defibrillator (CRT-D) that will allow him to safely undergo full-body magnetic resonance imaging (MRI) scans. Although "traditional" CRT-Ds are frequently used, this is the first time the device called Amplia MRI™ Quad CRT-D SureScan has been implanted in Canada. 
Heart failure occurs when the heart is unable to efficiently pump blood and oxygen to the body, causing symptoms such as shortness of breath, excessive tiredness and fluid retention. A CRT-D, also known as a biventricular pacemaker/defibrillator, is comprised of a pacemaker, a defibrillator and an additional third wire that allows sending electrical impulses to both lower chambers of the heart to help them beat in a more synchronized pattern. Surgically implanted just below the collarbone, CRT-Ds can improve heart function and reduce hospitalization and mortality. 
"CRT-Ds are often used in patients with severe heart failure, but a significant downside of this procedure has been that these patients are unable to undergo MRI scans after surgery because the strong magnetic fields generated by MRI affect the normal operation of the heart device," says Dr. Vidal Essebag, who is Director of Cardiac Electrophysiology at the MUHC and performed the surgery using the new implantable device. 
MRIs use magnetic fields to create a detailed internal view of the body, and are widely used to diagnose and plan the treatment of patients with a range of diseases and conditions. "MRIs have become the most powerful imaging method in cardiology, giving doctors invaluable information about the anatomy of the heart and about the areas of the heart that are scarred or abnormal, “says Dr. Essebag. "This information is vital, so the fact that we now have access to an MRI-compatible CRT-D device is a major advancement in the care of patients with severe heart failure." 
The new device was approved by Health Canada in May 2017. Medtronic, the manufacturer of the device, chose the MUHC to conduct the first Canadian implant because of Dr. Essebag’s expertise in electrophysiology and cardiac resynchronization therapy, and because of the institution’s renowned Heart Failure and Heart Transplant Centre. The centre treats complex care patients from the entire Réseau universitaire intégré de santé McGill (RUIS-McGil) – an area encompassing more than 60 per cent of the province. 
"Heart failure is the most rapidly increasing cardiovascular disease in Canada, affecting about half a million people." says Dr. Nadia Giannetti, who is Chief of Cardiology and Medical Director of the Heart Failure and Heart Transplant Centre at the MUHC. "In only the past year, around 3,400 Canadians benefited from a CRT-D, so it’s encouraging to know that an MRI-compatible device is now available in Canada."
-30-
About the McGill University Health Centre (MUHC): One of the world’s foremost academic health centres, the MUHC offers exceptional and integrated patient-centric care, research, teaching and technology assessment. Affiliated with the Faculty of Medicine of McGill University, the MUHC has a mandate to focus on complex care and is highly committed to working with partner organizations within the healthcare network, to ensure to the continuum of care in its community. The partner hospitals of the MUHC – The Montreal Children's Hospital, the Montreal General Hospital, the Royal Victoria Hospital, the Montreal Neurological Hospital, the Montreal Chest Institute and the Lachine Hospital of the MUHC – value multidisciplinary service throughout the lifespan, innovative technologies and practices, strategic partnerships and leadership in knowledge transfer. The MUHC is undergoing a Redevelopment Project at The Neuro, Lachine Hospital, and the Montreal General Hospital, which is designed to provide healthcare professionals with an effective environment in which to ensure patients and their families benefit from The Best Care for Life. Our establishments are also anchored in best sustainable-development practices, including LEED® Gold and BOMA BESt guidelines. www.muhc.ca 

Heart failure occurs when the heart is unable to efficiently pump blood and oxygen to the body, causing symptoms such as shortness of breath, excessive tiredness and fluid retention. A CRT-D, also known as a biventricular pacemaker/defibrillator, is comprised of a pacemaker, a defibrillator and an additional third wire that allows sending electrical impulses to both lower chambers of the heart to help them beat in a more synchronized pattern. Surgically implanted just below the collarbone, CRT-Ds can improve heart function and reduce hospitalization and mortality. 

"CRT-Ds are often used in patients with severe heart failure, but a significant downside of this procedure has been that these patients are unable to undergo MRI scans after surgery because the strong magnetic fields generated by MRI affect the normal operation of the heart device," says Dr. Vidal Essebag, who is Director of Cardiac Electrophysiology at the MUHC and performed the surgery using the new implantable device. 

MRIs use magnetic fields to create a detailed internal view of the body, and are widely used to diagnose and plan the treatment of patients with a range of diseases and conditions. "MRIs have become the most powerful imaging method in cardiology, giving doctors invaluable information about the anatomy of the heart and about the areas of the heart that are scarred or abnormal, “says Dr. Essebag. "This information is vital, so the fact that we now have access to an MRI-compatible CRT-D device is a major advancement in the care of patients with severe heart failure." 


The new device was approved by Health Canada in May 2017. Medtronic, the manufacturer of the device, chose the MUHC to conduct the first Canadian implant because of Dr. Essebag’s expertise in electrophysiology and cardiac resynchronization therapy, and because of the institution’s renowned Heart Failure and Heart Transplant Centre. The centre treats complex care patients from the entire Réseau universitaire intégré de santé McGill (RUIS-McGil) – an area encompassing more than 60 per cent of the province. 


"Heart failure is the most rapidly increasing cardiovascular disease in Canada, affecting about half a million people." says Dr. Nadia Giannetti, who is Chief of Cardiology and Medical Director of the Heart Failure and Heart Transplant Centre at the MUHC. "In only the past year, around 3,400 Canadians benefited from a CRT-D, so it’s encouraging to know that an MRI-compatible device is now available in Canada."

-30-


About the McGill University Health Centre (MUHC): One of the world’s foremost academic health centres, the MUHC offers exceptional and integrated patient-centric care, research, teaching and technology assessment. Affiliated with the Faculty of Medicine of McGill University, the MUHC has a mandate to focus on complex care and is highly committed to working with partner organizations within the healthcare network, to ensure to the continuum of care in its community. The partner hospitals of the MUHC – The Montreal Children's Hospital, the Montreal General Hospital, the Royal Victoria Hospital, the Montreal Neurological Hospital, the Montreal Chest Institute and the Lachine Hospital of the MUHC – value multidisciplinary service throughout the lifespan, innovative technologies and practices, strategic partnerships and leadership in knowledge transfer. The MUHC is undergoing a Redevelopment Project at The Neuro, Lachine Hospital, and the Montreal General Hospital, which is designed to provide healthcare professionals with an effective environment in which to ensure patients and their families benefit from The Best Care for Life. Our establishments are also anchored in best sustainable-development practices, including LEED® Gold and BOMA BESt guidelines. www.muhc.ca 

Contact 

Gilda Salomone

Agente de communications - Communications Officer

CUSM | MUHC Communications

Gilda [dot] Salomone [at] muhc [dot] mcgill [dot] ca